Clinical trial
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of…
NCT00363883 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00363883 |
|---|---|
| Title | Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium |
| Official title | Phase II Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Recurrent or Metastatic Transitional Cell Carcinoma of the Urothelium |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Transitional Cell Carcinoma of the Bladder |
| Intervention type | Drug, Other |
| Interventions | vorinostat, laboratory biomarker analysis |
| Enrollment | 14 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Aug 15, 2006 |
| Last update posted | Feb 13, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: